miR Scientific
miR Scientific is a precision healthcare company that commercializes the miR Sentinel™ Prostate Cancer Test, a non-invasive urine-based molecular diagnostic using its proprietary sncRNA scoring platform, serving healthcare providers, patients, and employers for prostate cancer detection and risk classification.
- Company typePrivate
- Founded2013
- HeadquartersRensselaer, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What miR Scientific does
miR Scientific (legal entity MiRNA Scientific) is a privately held precision healthcare company founded in 2013 and headquartered at 685 Route 1 South, Suite 110, North Brunswick, New Jersey. The company develops molecular diagnostic tests built on its proprietary miR Disease Management Platform®, which uses small non-coding RNA (sncRNA) interrogation techniques and a proprietary scoring algorithm to analyze RNA entities isolated from urinary exosomes. Its flagship commercial product, the miR Sentinel™ Prostate Cancer Test, is positioned as the first and only non-invasive liquid biopsy urine test that detects, classifies, and monitors prostate cancer at the molecular level without requiring PSA, Digital Rectal Exam, or biopsy. The test delivers one of three categorical results: No Molecular Evidence of Prostate Cancer, Low Risk, or Elevated Risk for aggressive disease.
The company addresses prostate cancer screening inefficiency, citing up to 70% of diagnostic core needle biopsies as unnecessary and over 60% of age-eligible men remaining unscreened. Its go-to-market is enterprise field sales targeting healthcare providers who order the test for patients, supplemented by an employer health-program channel. Revenue is generated on a transaction-fee basis per test, with no publicly disclosed pricing. Customers are segmented horizontally into healthcare providers (primary), patients, and employers.
The product roadmap signaled by the company is platform-based: the prostate test is described as the initial deliverable from a broader cancer management platform, with stated intent to extend into additional urological and other cancers. The firm holds registered trademarks for the miR Disease Management Platform® and miR Sentinel™ brand. Leadership includes co-founders Sam Salman (CEO) and Martin Tenniswood (CSO), with Erik Johnson as COO and Robert Tenniswood as President. The firm reports 101–250 employees and is operating, but discloses no funding rounds, revenue, payor coverage, regulatory milestones, or named commercial customers in the source material.
miR Scientific firmographics
Firmographics- Name
- miR Scientific
- Legal name
- MiRNA Scientific
- Website
- https://mirscientific.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- miR Scientific is a precision healthcare company that commercializes the miR Sentinel™ Prostate Cancer Test, a non-invasive urine-based molecular diagnostic using its proprietary sncRNA scoring platform, serving healthcare providers, patients, and employers for prostate cancer detection and risk classification.
- Ownership category
- akta.pro rank
miR Scientific industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where miR Scientific is headquartered
LocationHeadquarters
- HQ city
- Rensselaer
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
miR Scientific business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Diagnostic Test Services: The company generates revenue through the sale of its miR Sentinel Prostate Cancer Test, a molecular diagnostic urine test. Healthcare providers order the test for patients, with results delivered to providers and patients indicating cancer presence and risk level.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
miR Scientific product offering
Product offeringCore offering
miR Scientific develops and delivers the miR Sentinel™ Prostate Cancer Test, a non-invasive liquid biopsy urine test that detects, classifies and monitors prostate cancer at the molecular level. The test analyzes RNA genetic material isolated from urinary exosomes using the company's proprietary miR Disease Management Platform® and sncRNA interrogation techniques, delivering results without reliance on PSA, DRE or biopsy.
Product overview
MiRNA Scientific is a precision healthcare company operating with a single unified product: the proprietary miR Disease Management Platform® which delivers the miR Sentinel™ Prostate Cancer Test. The platform combines advanced sncRNA interrogation techniques with a proprietary scoring algorithm to analyze RNA genetic material from urine samples. Currently focused on urological cancers, the miR Sentinel test is the company's flagship offering and the first non-invasive urine-based liquid biopsy for prostate cancer detection and classification.
Differentiator
Problem solved
Functional benefit
Brands
- miR Sentinel: The miR Sentinel™ Prostate Cancer Test is the first and only non-invasive liquid biopsy urine test that accurately detects, classifies and monitors prostate cancer at the molecular level.
- miR Disease Management Platform
Products and services
- miR Sentinel™ Prostate Cancer Test The first and only non-invasive liquid biopsy urine test that accurately detects, classifies, and monitors prostate cancer at the molecular level. Delivers results indicating 'No Molecular Evidence of Prostate Cancer,' 'Low Risk,' or 'Elevated Risk' for aggressive disease from a single urine sample without requiring PSA, DRE, or biopsy. Intended for healthcare providers ordering on behalf of patients and for workplace screening programs.
Quantifiable outcome
- 99% survival rate with early-stage diagnosis
- +2 more outcomes
Companies that use miR Scientific
Customer profileSegments3 records
Ideal customer profiles3 records
miR Scientific technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
miR Scientific partnerships and signals
Strategic signalScale indicators5 records
Recent moves4 records
Expansion highlights4 records
miR Scientific competitors and assessment
Company assessmentDirect peers
- Exact Sciences: Commercial-stage molecular diagnostics company best known for Cologuard, a non-invasive stool-based cancer screening test. Directly comparable to miR Scientific as a non-invasive, sample-based molecular cancer detection test sold through providers, with the same go-to-market motion of replacing or augmenting invasive standard-of-care procedures.
- Guardant Health: Leading liquid biopsy company with blood-based cancer detection and monitoring tests (e.g., Guardant360, Shield). Comparable to miR Scientific in using cell-free molecular signals for cancer detection/monitoring, though Guardant operates in blood rather than urine.
- Natera: Molecular diagnostics company with cell-free DNA-based tests across oncology and reproductive health. Comparable as a commercial-stage liquid biopsy player with a provider-channel sales model and similar clinical evidence + payor coverage go-to-market requirements.
Broad incumbents
- Myriad Genetics: Established molecular diagnostics company with oncology, urology, and women's health tests including Prolaris for prostate cancer risk. Comparable as a urology-focused molecular diagnostics provider and broad incumbent in the same clinical category miR Scientific targets.
- Veracyte: Genomic diagnostics company with urology offerings (e.g., Decipher Prostate) for prostate cancer risk stratification. Comparable as a molecular diagnostics player addressing the prostate cancer pathway with provider-channel sales and similar payor/reimbursement dynamics.
- Bio-Techne: Life science tools and diagnostics company with proteomics and molecular biology products serving research and clinical diagnostics markets. Comparable in biomarker-based analytical capabilities that underpin miR Scientific's RNA-based detection approach.
- NeoGenomics: Clinical oncology laboratory services company providing molecular and genetic testing for cancer. Comparable as a clinical lab services platform that processes and reports specialized cancer diagnostic tests to providers.
- OPKO Health (BioReference Laboratories): Diversified healthcare company operating BioReference Laboratories, a major clinical diagnostics lab. Comparable as a large-scale clinical lab with urology and oncology test menus, including the 4Kscore prostate cancer test that directly competes in the same clinical workflow.
Emerging players
- Grail: Multi-cancer early detection company developing blood-based Galleri test. Comparable in using cell-free molecular signals to detect cancer non-invasively and in targeting large screening populations, though operating in blood rather than urine.
- DiaCarta: Molecular diagnostics company developing liquid biopsy and cancer detection tests, including urine-based oncology tests. Comparable as a smaller, emerging player in non-invasive molecular cancer diagnostics with overlapping technology and customer segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
miR Scientific social profiles
Digital presencemiR Scientific financial estimates
Financial estimateRevenue estimate
Valuation estimate
miR Scientific leadership team
Management profileNumber of profiles
Profiles4 records
miR Scientific funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
miR Scientific M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about miR Scientific
What does miR Scientific do?
miR Scientific develops and delivers the miR Sentinel™ Prostate Cancer Test, a non-invasive liquid biopsy urine test that detects, classifies and monitors prostate cancer at the molecular level. The test analyzes RNA genetic material isolated from urinary exosomes using the company's proprietary miR Disease Management Platform® and sncRNA interrogation techniques, delivering results without reliance on PSA, DRE or biopsy.
Is miR Scientific a public or private company?
miR Scientific is a private company. It is classified as unknown and is currently operating.
When was miR Scientific founded?
miR Scientific was founded in 2013. It employs 101 to 250 people.
Where is miR Scientific based?
miR Scientific is headquartered in Rensselaer, United States, in the North America region.
How does miR Scientific make money?
One revenue line is on record: diagnostic Test Services.
Who are miR Scientific's main competitors?
Direct peers on record are Exact Sciences, Guardant Health and Natera. Broad incumbents are Myriad Genetics, Veracyte, Bio-Techne, NeoGenomics and OPKO Health (BioReference Laboratories). Emerging players are Grail and DiaCarta.
Does miR Scientific have an API?
No public API is recorded for miR Scientific.
What industry is miR Scientific in?
miR Scientific's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 8071.